Nitrase Therapeutics (formerly Nitrome Biosciences) uses its proprietary NITROME platform to discover and develop therapeutics that modulate a newly identified class of enzymes termed nitrases. The company has assembled a pipeline aimed at a broad set of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s disease, other neurodegenerative diseases, macular degeneration, fibrosis and cancer. Its lead program is targeting Parkinson’s disease and is being advanced toward human clinical proof-of-concept studies. The company changed its name to better reflect its discovery platform and announced the appointment of Pierre Beaurang, Ph.D., as CEO to accelerate program development and partnerships. Nitrase has been recognized with awards including a Target Advancement grant from The Michael J. Fox Foundation for Parkinson’s Research. The company expanded its Series A financing to support continued advancement of its lead program and exploration of additional nitrase-dependent indications. Nitrome Biosciences is a San Francisco, CA-based biopharmaceutical company building a platform around a newly identified class of enzymes called Nitrases. Its lead programs target Parkinson’s disease with the goal of developing therapies that could slow or halt disease progression. The company intends to expand its proprietary platform to other age-related disorders beyond Parkinson’s. Led by Founder, CEO and CSO Dr. Irene Griswold-Prenner, Nitrome is advancing its lead program toward human clinical proof-of-concept studies. Financially, the company completed a $38M Series A financing to fund these development and platform-expansion efforts. No operating metrics (revenue/users) were disclosed in the article.

Total raised

$83M

Funding rounds

2

Latest round

Series A

Latest activity

Nov 2021